Immune Checkpoint Inhibitors in Malignant Pleural Mesothelioma: Efficacy, Real-World Outcomes, and the Search for Predictive Biomarkers

Immunotherapy has significantly reshaped the management of malignant pleural mesothelioma (MPM), offering new therapeutic opportunities after decades in which platinum–pemetrexed chemotherapy represented the only systemic option. However, clinical benefit remains markedly heterogeneous, with outcome...

وصف كامل

التفاصيل البيبلوغرافية

المؤلفون الرئيسيون:	Giusi Bondì, Serafina Martella, Dimitrios Stylianakis, Alberto Terminella, Filippo Lococo, Alessia Ciarrocchi, Alfonso Fiorelli, Giacomo Cusumano
التنسيق:	Artigo
اللغة:	Inglês
منشور في:	MDPI AG 2026-02-01
سلاسل:	Current Oncology
الموضوعات:	malignant pleural mesothelioma immune checkpoint inhibitors biomarkers tumor microenvironment genomic alterations immunotherapy outcomes
الوصول للمادة أونلاين:	https://www.mdpi.com/1718-7729/33/2/93
الوسوم:	إضافة وسم لا توجد وسوم, كن أول من يضع وسما على هذه التسجيلة!